Jane R. Kenny - Concepedia

Author

Jane R. Kenny

Sunesis (United States)

Also Known As

J J Kenny, J R Kenny, J. KENNY, J. Kenny, J. R. Kenny, J.R. Kenny, Jane Kenny, Jane R Kenny, Jane R. Kenny

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Sunesis (United States)Gene Therapy Laboratory AstraZeneca (United Kingdom)Loughborough University University of Manchester

About

Jane R. Kenny is an author at Sunesis (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	27	1.3K
2	Biochemistry	11	11	550
3	Natural Sciences	9	9	470
4	Health Sciences	3	3	182
5	Engineering	2	2	63

Jane R. Kenny

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies Yuan Chen, Jin Y. Jin, Sophie Mukadam, Biopharmaceutics & Drug Disposition Physiologically Based PharmacokineticsPharmacokinetic ModelingPreclinical Drug EvaluationProspective PredictionPharmacology	2012	110
A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease–Drug Interactions: Suppression of CYP3A by IL-6 Krishna K. Machavaram, Lisa M. Almond, Amin Rostami‐Hodjegan, Clinical Pharmacology & Therapeutics Cytokine LevelsImmunologyPhysiologically-based Pharmacokinetic ModelingPharmacodynamic ModelingSystems Pharmacology	2013	107
In Vitro–In Vivo Extrapolation of Clearance: Modeling Hepatic Metabolic Clearance of Highly Bound Drugs and Comparative Assessment with Existing Calculation Methods Patrick Poulin, Jane R. Kenny, Cornelis E. C. A. Hop, Journal of Pharmaceutical Sciences Physiologically-based Pharmacokinetic ModelingPharmacodynamic ModelingVitro–in Vivo ExtrapolationHepatotoxicityDrug Absorption	2011	105
EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES Dermot F. McGinnity, Amanda J. Berry, Jane R. Kenny, Drug Metabolism and Disposition	2006	99
Syntheses and Characterization of the Acyl Glucuronide and Hydroxy Metabolites of Diclofenac Jane R. Kenny, James L. Maggs, Xiaoli Meng, Journal of Medicinal Chemistry	2004	99
Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model Lisa M. Almond, Sophie Mukadam, I. Gardner, Drug Metabolism and Disposition	2016	99
AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS Anthony C. Atkinson, Jane R. Kenny, Ken Grime Drug Metabolism and Disposition	2005	96
Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug–Drug Interaction Prediction Jane R. Kenny, Sophie Mukadam, Chenghong Zhang, Pharmaceutical Research Drug InteractionsMarketed Oncology DrugsPreclinical Drug EvaluationPharmacological StudyMedicine	2012	94
Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors Janusz J. Kulagowski, Wade Blair, Richard J. Bull, Journal of Medicinal Chemistry RheumatologyMedicinal ChemistryDrug TargetBiochemistryMedicine	2012	91
Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors Emily J. Hanan, Anne van Abbema, Kathy Barrett, Journal of Medicinal Chemistry Lead CompoundsDrug TargetChemoprevention StrategyPharmacotherapyChemical Biology	2012	89

Page 1